News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Simcere Pharmaceutical Group Passes EU-GMP Inspection for OTC Diarrhea Treatment


8/23/2011 11:44:05 AM

August 23, 2011 -- Simcere Pharma reported that Biqi, the company’s branded generic anti-diarrhea drug, has passed EU-GMP inspection. The certificate was issued following an audit that covered product formulation, manufacturing process, facilities and quality management systems. In 2010, Simcere's manufacturing facility for diosmectite, the API in Biqi, successfully passed EU-GMP inspection. Simcere makes innovative cancer treatments and branded generics, all of which are distributed in China. Simcere should now be able to market Biqi in Europe, though it did not announce any plans to do so. More details....

Stock Symbol: (NYSE: SCR)


Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES